SAB Biotherapeutics Investigational Influenza Therapeutic Launch
SAB Biotherapeutics has made an exciting announcement regarding their investigational therapeutic, SAB-176, which has received Breakthrough Therapy Designation (BTD) from the FDA.
This designation recognizes the potential of SAB-176 in providing post-exposure prophylaxis for high-risk patients susceptible to Type A and Type B influenza, including those with strains resistant to antiviral treatments.
SAB-176 is currently undergoing development for various influenza indications, including the treatment of high-risk patient populations and pre-and post-exposure prophylaxis.
The recent BTD from the FDA validates the unique approach of SAB-176, which utilizes a multi-epitope targeting modality, setting it apart from monoclonal antibodies that only bind to a single epitope.
By employing this novel treatment approach, SAB-176 demonstrates the ability to maintain its effectiveness against viral mutations and effectively mitigate the risk of emerging influenza strains that may be resistant to conventional treatments.
It addresses the challenge of viruses evolving in response to vaccines or treatments, which can lead to the emergence of treatment-resistant variants known as "escape mutants."
In the SAB-176-201 clinical trial, evidence showed that SAB-176 significantly reduced the time to resolution of positive viral culture compared to the control group.
Additionally, data from SAB's DiversitAb™ platform indicated that the multi-epitope binding modality of SAB's biologic treatments effectively lowers the risk of treatment-resistant viruses emerging.
Preclinical evidence further supports the scientific basis for the Breakthrough Therapy designation, demonstrating the in vivo efficacy of SAB-176 against treatment-resistant strains.
Overall, the Breakthrough Therapy designation for SAB-176 marks a significant advancement in the field of influenza immunotherapy, offering the promising potential for post-exposure prophylaxis in high-risk individuals and addressing the challenge of emerging treatment-resistant influenza strains.
